CA2168647A1 - Preparations monogenes de conjugues cytotoxiques - Google Patents

Preparations monogenes de conjugues cytotoxiques

Info

Publication number
CA2168647A1
CA2168647A1 CA002168647A CA2168647A CA2168647A1 CA 2168647 A1 CA2168647 A1 CA 2168647A1 CA 002168647 A CA002168647 A CA 002168647A CA 2168647 A CA2168647 A CA 2168647A CA 2168647 A1 CA2168647 A1 CA 2168647A1
Authority
CA
Canada
Prior art keywords
fgf
modified
saporin
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168647A
Other languages
English (en)
Inventor
Barbara A. Sosnowski
Douglas A. Lappi
Andrew J. Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whittier Institute for Diabetes and Endocrinology
Selective Genetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168647A1 publication Critical patent/CA2168647A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des préparations monogènes de conjugués de facteurs de croissance de fibroblastes (FGF) avec des agents cytotoxiques. Pratiquement la totalité des conjugués cytotoxiques de la préparation monogène contient le même rapport molaire agent cytotoxique/polypeptide réagissant avec un récepteur de FGF. On prépare les conjugués par conjugaison chimique et, également, par expression d'ADN codant le conjugué, de façon à produire des protéines de fusion. On prépare les conjugués par réaction de FGF, dont au moins une des cystéines réactives est remplacée ou supprimée, avec de la saporine purifiée et monodérivée ou avec de la saporine modifiée au niveau ou à proximité d'une terminaison par addition d'un résidu de cystéine ou remplacement d'un résidu avec cystéine. Les préparations obtenues sont sensiblement monogènes. On produit des protéines de fusion par expression de produits de recombinaison d'ADN codant des mutéines d'un FGF dans lequel une ou plusieurs parmi toutes les cystéines réactives ont été supprimées ou remplacées en liaison avec l'ADN codant un agent cytotoxique. Les produits de recombinaison d'ADN sont exprimés dans des cellules hôtes, afin de produire des préparations monogènes de conjugués cytotoxiques de FGF. Dans des modes de réalisation dans lesquels la partie de FGF du conjugué a été modifiée, de manière qu'aucune cystéine n'est disponible pour une réaction, les compositions obtenues sont exemptes d'agrégats. Les préparations monogènes de conjugués sont un agent cytocide efficace contre des cellules porteuses du récepteur de FGF.
CA002168647A 1993-08-02 1994-07-27 Preparations monogenes de conjugues cytotoxiques Abandoned CA2168647A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9992493A 1993-08-02 1993-08-02
US08/099,924 1993-08-02
US14582993A 1993-10-29 1993-10-29
US08/145,829 1993-10-29

Publications (1)

Publication Number Publication Date
CA2168647A1 true CA2168647A1 (fr) 1995-02-09

Family

ID=26796629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168647A Abandoned CA2168647A1 (fr) 1993-08-02 1994-07-27 Preparations monogenes de conjugues cytotoxiques

Country Status (5)

Country Link
EP (1) EP0712314A1 (fr)
JP (1) JPH09503751A (fr)
AU (1) AU7475694A (fr)
CA (1) CA2168647A1 (fr)
WO (1) WO1995003831A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008293A1 (fr) * 1992-12-23 1996-03-21 Patrick Edison Kane Balle de golf moulee par injection et soluble dans l'eau
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1995024928A2 (fr) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil
WO1996006641A1 (fr) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugues du facteur de croissance endothelial vasculaire avec des agents cibles
AU3724495A (en) * 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
SI0804479T1 (sl) * 1994-10-13 2006-12-31 Amgen Inc Metoda zdravljenja sladkorne bolezni z uporabo kgf
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
JP3708210B2 (ja) 1996-04-03 2005-10-19 協和醗酵工業株式会社 抗線維芽細胞増殖因子−８モノクローナル抗体
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JP2001505426A (ja) 1996-11-27 2001-04-24 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 線維芽細胞増殖因子１３
NZ504565A (en) * 1997-11-17 2002-11-26 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations of eprosartan used to block angiotensin II (AII) receptors in the treatment of hypertension, congestive heart failure and renal failure
CA2316015A1 (fr) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Formulations du facteur-2 de croissance des keratinocytes
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
PL373511A1 (en) * 2001-05-15 2005-09-05 Faulk Pharmaceuticals, Inc. Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
PL238516B1 (pl) * 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
CN111358937A (zh) * 2020-02-27 2020-07-03 广州领晟医疗科技有限公司 Fgf-2衍生多肽在制备促进软骨修复和/或治疗骨关节炎药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638402B2 (en) * 1987-11-24 1993-07-01 Amgen, Inc. Analogs of fibroblast growth factor
GB8801877D0 (en) * 1988-01-28 1988-02-24 Erba Carlo Spa Nucleotide sequence encoding plant ribosome inactivating protein
WO1992004918A1 (fr) * 1990-09-19 1992-04-02 The Salk Institute For Biological Studies Traitement des etats physiopathologiques tumorigenes a l'aide de conjugues de facteur de croissance fibroblastique (fcf) et d'un agent cytotoxique
AU685058B2 (en) * 1992-06-16 1998-01-15 Selective Genetics, Inc. Recombinant production of saporin-containing proteins

Also Published As

Publication number Publication date
EP0712314A1 (fr) 1996-05-22
JPH09503751A (ja) 1997-04-15
WO1995003831A1 (fr) 1995-02-09
AU7475694A (en) 1995-02-28

Similar Documents

Publication Publication Date Title
CA2168647A1 (fr) Preparations monogenes de conjugues cytotoxiques
AU702323B2 (en) Heparin-binding growth factors for gene therapy and anterior eye disorders
US6037329A (en) Compositions containing nucleic acids and ligands for therapeutic treatment
US5576288A (en) Fibroblast growth factor conjugates
EP0382781B1 (fr) Composition pour le traitement des cancers caracterises par la surexpression du proto-oncogene c-fms
WO1996006641A1 (fr) Conjugues du facteur de croissance endothelial vasculaire avec des agents cibles
US5191067A (en) Fibroblast growth factor conjugates
WO1996008274A2 (fr) Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
US20090093400A1 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity
US5916772A (en) Recombinant production of saporin-containing proteins
EP0833665A1 (fr) Compositions contenant des acides nucleiques et des ligands pour un traitement therapeutique
CA2295189C (fr) Proteine de type 1 inactivant un ribosome
KR102629006B1 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN111386130A (zh) 长效单链胰岛素类似物及其缀合物
US5084556A (en) Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
EP0923387B1 (fr) Instruments medicaux recouverts d' heparine a usage intraveineux contenant des conjugues de facteur de croissance des fibroblastes
WO1997049434A9 (fr) Instruments medicaux heparines contenant des conjugues de facteur de croissance des fibroblastes
US20030040496A1 (en) Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles
WO1989004839A1 (fr) Molecules de ricin et conjugues de toxines de ricin ameliores
US20050090445A1 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity

Legal Events

Date Code Title Description
FZDE Dead